News | Antiplatelet and Anticoagulation Therapies | February 13, 2018

Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial

XIENCE 28 Study will evaluate whether patients at high risk of bleeding can safely receive blood thinners for as short as 28 days after receiving drug-eluting stent

Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial

February 13, 2018 — Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet therapy (DAPT) in patients at high risk of bleeding after implantation with a Xience everolimus-eluting coronary stent. The first patient was enrolled into the  XIENCE 28 GLOBAL DAPT study by Prof. Emanuele Barbato, M.D., Ph.D., a cardiologist at OLV-Hospital Aalst in Belgium.

Patients who receive a stent are generally prescribed blood-thinning medicines to reduce the risk of stent thrombosis. However, blood thinning medicines can increase the risk of bleeding for some patients due to factors such as older age, chronic use of anticoagulant medications, anemia and renal disease[1],[2].

"While blood thinning medicines are important to prevent clots after a stent is implanted, we want to limit the duration of these medications for people who are at high risk of bleeding," said Marco Valgimigli, M.D., Ph.D., associate professor of cardiology and senior interventional cardiologist at the Universitätsspital in Bern, Switzerland, and co-principal investigator of the study. "This trial will help determine if high-bleeding risk patients can safely reduce their duration of blood thinning medication to as short as 28 days."

In Europe, most patients at high risk of bleeding are currently treated with DAPT for three to six months after receiving a drug-eluting stent, according to EU treatment guidelines.[3]

XIENCE 28 GLOBAL is a prospective, single-arm, multi-center, open label, non-randomized study. The goal of the study is to assess whether one month of treatment with DAPT is non-inferior to at least six months of DAPT in high-bleeding risk patients. The primary endpoint is a composite rate of myocardial infarction, stent thrombosis, death, stroke or major bleeding between one and six months. Approximately 800 patients will be enrolled at 50 sites across Europe and Asia.

For more information: www.xiencestent.com/featured-trials

 

Related DAPT Content

Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents

Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients

Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Key Interventional Cardiac Technology Updates to Prepare for TCT 2017

Questions Remain on DAPT Prolongation

 

References

1. Shanmugam VB, Harper R, Meredith I, Malaiapan Y, Psaltis PJ. An overview of PCI in the very elderly. J Geriatr Cardiol 2015;174−184.

2. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114:774–82.

3. Valgimigli M, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2017 Aug 26. doi: 10.1093/eurheartj/ehx419.

Related Content

Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for...
Overlay Init